Treatment of Hairy Cell Leukemia with Granulocyte Colony-Stimulating Factor and Recombinant Consensus Interferon or Recombinant Interferon-Alpha-2b

Glaspy, John A.; Souza, Lawrence M.; Scates, Steven M.; Narachi, M. A.; Blatt, Lawrence M.; Ambersley, Janice; Golde, David W.

doi:10.1097/00002371-199204000-00007

Cited by 12 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This appeared to be the case in the three patients treated with IFN before starting 2-CdA. Some authors have reported the potential usefulness of the haemopoietic growth factor G-CSF as an adjunct to IFN for reducing neutropenic complications (Glaspy et al, 1992). In the light of our study, we suggest that patients with unfavourable presenting features first receive IFN therapy for 6 months (eventually in combination with G-CSF), in order to decrease tumour burden and improve cytopenia before 2-CdA treatment.…”

Section: Discussionmentioning

confidence: 71%

Treatment of hairy cell leukaemia (HCL) with 2‐chlorodeoxyadenosine (2‐CdA): identification of parameters predictive of adverse effects

Legrand

Vekhoff²,

Marie

et al. 1997

Br J Haematol

View full text Add to dashboard Cite

Summary. 2-chlorodeoxyadenosine (2-CdA) induces high complete remission (CR) rates in hairy cell leukaemia (HCL), but is associated with serious toxicities. Therefore we reviewed our experience with 2-CdA in 16 HCL patients, with special attention to adverse effects. One-third of patients presented severe neutropenic infections and/or required prolonged blood support. Patients with low tumour mass and moderate cytopenias were more likely to achieve CR, whereas those with high tumour burden and severe bone marrow impairment were at increased risk of severe infection and blood product requirements. All these unfavourable parameters may be corrected by short-term alphainterferon (IFN) therapy. Therefore we suggest that patients with unfavourable presenting features might benefit from IFN therapy before 2-CdA.

show abstract

Section: Discussionmentioning

confidence: 71%

Treatment of hairy cell leukaemia (HCL) with 2‐chlorodeoxyadenosine (2‐CdA): identification of parameters predictive of adverse effects

Legrand

Vekhoff²,

Marie

et al. 1997

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…Several approaches on how to best combine the use of granulocytic growth factors for the treatment of patients with HCL have been reported; the first, described by Glaspy et al [18], combined the use of G-CSF with interferon-α [19]. Saven et al [10] used priming therapy with filgrastim followed by cladribine and additional filgrastim in 35 patients, comparing them to 105 historical controls with HCL who had not received the growth factor.…”

Section: Tablementioning

confidence: 99%

Pegfilgrastim Prophylaxis for Cladribine-Induced Neutropenia in Patients with Hairy-Cell Leukemia

Goldschmidt¹,

Ganzel²,

Attias³

et al. 2014

Acta Haematol

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor (rh G-CSF) as an adjunct to interferon alpha therapy of neutropenic patients with hairy cell leukemia

et al. 1993

View full text Add to dashboard Cite

Six patients with hairy cell leukemia (HCL) and neutropenia (median neutrophil count 563/microliters, range 30-1200) were treated with recombinant human granulocyte colony-stimulating factor (G-CSF) at a dose of 5 micrograms/kg by daily subcutaneous injection as an adjunct to interferon-alpha (IFN-a) therapy, in order to ameliorate neutropenia. Five of six patients responded to G-CSF with normalization of neutrophil counts (> 1800/microliters) within 2-11 days and a median neutrophil count of 5211/microliters (range 4312-10160) at the end of G-CSF therapy. In three of these patients, infections resolved when neutropoiesis recovered. In one patient with very severe neutropenia (30/microliters), in whom myeloid progenitors were not detectable, G-CSF therapy failed to restore granulopoiesis. Cessation or interruption of G-CSF after 2-5 weeks of therapy resulted in a rapid decline of neutrophil counts to lower or subnormal levels (median value 1478/microliters, range 770-2739) within 1 week, suggesting that the improvement of granulopoiesis was dependent on G-CSF and not due to IFN-a therapy. G-CSF may be a useful adjunct to IFN-a therapy in patients with HCL in order to manage or prevent neutropenic complications in the early phase of treatment.

show abstract

Treatment of Hairy Cell Leukemia with Granulocyte Colony-Stimulating Factor and Recombinant Consensus Interferon or Recombinant Interferon-Alpha-2b

Cited by 12 publications

References 0 publications

Treatment of hairy cell leukaemia (HCL) with 2‐chlorodeoxyadenosine (2‐CdA): identification of parameters predictive of adverse effects

Treatment of hairy cell leukaemia (HCL) with 2‐chlorodeoxyadenosine (2‐CdA): identification of parameters predictive of adverse effects

Pegfilgrastim Prophylaxis for Cladribine-Induced Neutropenia in Patients with Hairy-Cell Leukemia

Granulocyte colony-stimulating factor (rh G-CSF) as an adjunct to interferon alpha therapy of neutropenic patients with hairy cell leukemia

Contact Info

Product

Resources

About